Rimiterol API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Rimiterol | CAS No: 32953-89-2 | GMP-certified suppliers
A medication that serves as a selective beta-2 adrenergic agonist for potential use in treating obstructive airway diseases such as asthma and COPD by relaxing bronchial smooth muscle.
Therapeutic categories
Product Snapshot
- Rimiterol is an oral small molecule formulation
- It is primarily investigated for respiratory conditions such as asthma and chronic obstructive pulmonary disease
- Currently, Rimiterol holds an experimental status with no active regulatory approvals
Clinical Overview
Although no specific clinical indications have been formally established for rimiterol, its classification suggests potential use in conditions involving bronchoconstriction, such as asthma or chronic obstructive pulmonary disease (COPD), where beta-2 agonists function to relax airway smooth muscle. The mechanism of action, consistent with selective beta-2 adrenergic agonism, involves activation of beta-2 receptors leading to increased intracellular cyclic AMP and subsequent smooth muscle relaxation in the bronchial tree.
Pharmacokinetic details including absorption, distribution, metabolism, and excretion (ADME) parameters are not documented. Similarly, comprehensive pharmacodynamic data and clinical safety profiles are unavailable. However, as an agent producing tachycardia and hypertension, typical cardiovascular effects associated with beta-2 adrenergic agonists should be considered. Safety and toxicity information remains limited, reflecting its status as an experimental compound without full regulatory approvals or widespread clinical use.
No branded pharmaceutical products incorporating rimiterol are currently authorized for medical use, positioning it primarily as a molecule of research interest within neuropharmacology and airway disease pharmacotherapy.
From an API sourcing perspective, stringent quality control is crucial due to its catechol structure, which can be susceptible to oxidation. Suppliers should ensure compliance with Good Manufacturing Practices (GMP) and provide detailed characterization data including purity, impurity profiles, and stability information to support formulation development and regulatory submissions.
Identification & chemistry
| Generic name | Rimiterol |
|---|---|
| Molecule type | Small molecule |
| CAS | 32953-89-2 |
| UNII | 26GIW6ZLPH |
| DrugBank ID | DB13559 |
Formulation & handling
- Rimiterol is a small molecule with moderate water solubility, suitable for oral formulation development.
- Its catechol functional group may require consideration for oxidation stability during handling and storage.
- The low logP value suggests limited lipophilicity, which may influence its absorption and formulation strategies.
Regulatory status
Rimiterol is a type of Respiratory Tract Agents
Respiratory Tract Agents are a vital category of pharmaceutical APIs (Active Pharmaceutical Ingredients) designed to treat respiratory conditions and diseases. These agents are specifically formulated to target the respiratory system, which includes the lungs, airways, and nasal passages. They play a crucial role in managing various respiratory disorders, such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis.
Respiratory Tract Agents encompass a wide range of medications, including bronchodilators, corticosteroids, antihistamines, and mucolytics. Bronchodilators are commonly used to relieve airway constriction and facilitate smooth breathing by relaxing the muscles in the airways. Corticosteroids help reduce inflammation in the respiratory system, alleviating symptoms and preventing exacerbations. Antihistamines work by blocking histamine receptors, thus mitigating allergic reactions that often impact the respiratory tract. Mucolytics aid in loosening and thinning mucus, making it easier to expel from the airways.
These APIs are developed through rigorous research and development processes, ensuring their efficacy, safety, and compliance with regulatory standards. Pharmaceutical manufacturers rely on advanced technologies and stringent quality control measures to produce high-quality Respiratory Tract Agents. These APIs are subsequently incorporated into various dosage forms, including inhalers, nasal sprays, nebulizers, and oral medications.
Respiratory Tract Agents are essential in the management of respiratory conditions, providing relief from symptoms, improving lung function, and enhancing the overall quality of life for patients. They are prescribed by healthcare professionals and often used in combination therapies to achieve optimal results. As respiratory disorders continue to affect a significant portion of the global population, the development and availability of effective Respiratory Tract Agents play a vital role in addressing these health challenges and improving patient outcomes.
